Literature DB >> 19896917

Breast cancer as a global health concern.

Steven S Coughlin1, Donatus U Ekwueme.   

Abstract

Public health data indicate that the global burden of breast cancer in women, measured by incidence, mortality, and economic costs, is substantial and on the increase. Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, and more than 410,000 will die from the disease. In low- and middle-income countries (LMCs), the infrastructure and resources for routine screening mammography are often unavailable. In such lower resource settings, breast cancers are commonly diagnosed at late stages, and women may receive inadequate treatment, pain relief, or palliative care. There have been an increasing number of global health initiatives to address breast cancer including efforts by Susan G. Komen for the Cure((c)), the Breast Health Global Initiative (BHGI), the U.S. Centers for Disease Control and Prevention (CDC), the American Cancer Society, the National Cancer Institute (NCI), and ongoing work by leading oncology societies in different parts of the world. To support such initiatives, and to provide a scientific evidence base for health policy and public health decision making, there is a need for further health services research and program evaluations. Cancer registries can be invaluable in ascertaining the magnitude of cancer disease burden and its distribution in these countries. Additional data are needed for various geographic areas to assess resources required, cost-effectiveness, and humane approaches for preventing or controlling breast cancer in low resource settings in developing countries.

Entities:  

Mesh:

Year:  2009        PMID: 19896917     DOI: 10.1016/j.canep.2009.10.003

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  164 in total

1.  Effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial.

Authors:  Alireza Ostadrahimi; Ali Esfahani; Mohammad Asghari Jafarabadi; Jamal Eivazi Ziaei; Aliakbar Movassaghpourakbari; Nazila Farrin
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

3.  Interaction of occupational and personal risk factors in workforce health and safety.

Authors:  Paul A Schulte; Sudha Pandalai; Victoria Wulsin; HeeKyoung Chun
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

4.  Communicating evidence-based information on cancer prevention to state-level policy makers.

Authors:  Ross C Brownson; Elizabeth A Dodson; Katherine A Stamatakis; Christopher M Casey; Michael B Elliott; Douglas A Luke; Christopher G Wintrode; Matthew W Kreuter
Journal:  J Natl Cancer Inst       Date:  2011-01-06       Impact factor: 13.506

Review 5.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

6.  Exploring molecular pathways of triple-negative breast cancer.

Authors:  Valeria Ossovskaya; Yipeng Wang; Adam Budoff; Qiang Xu; Alexander Lituev; Olga Potapova; Gordon Vansant; Joseph Monforte; Nikolai Daraselia
Journal:  Genes Cancer       Date:  2011-09

7.  What Is the Status Quo of Breast Cancer Research at Germany's Universities?

Authors:  Rolf Kreienberg; Achim Wöckel
Journal:  Breast Care (Basel)       Date:  2010-02-26       Impact factor: 2.860

8.  Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma.

Authors:  Omer Sager; Ferrat Dincoglan; Bora Uysal; Selcuk Demiral; Hakan Gamsiz; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu
Journal:  Jpn J Radiol       Date:  2018-04-05       Impact factor: 2.374

9.  CoCl2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells.

Authors:  Qing Li; Rong Ma; Mei Zhang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

10.  Mutation and protein expression analysis of CYP1A1 gene-a study on female breast cancer cases from India.

Authors:  Mohammad Zeeshan Najm; Salman Akhtar; Istaq Ahmad; Shilpi Chattopadhyay; Nasar Mallick; Sarah Siddiqui; Shuaib Zaidi; Waseem Ahmad Siddiqui; Syed Akhtar Husain
Journal:  Tumour Biol       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.